retatrutide triple agonist glp-1 gip glucagon phase 3 2025 peptide for weight loss and fat burning Cagrilintide vs Retatrutide Compared |

Now at month eight, sitting at 156 pounds

Gallbladder Disease: There is an increased risk of gallstones and other gallbladder-related issues, possibly due to the drugs effects on fat metabolism

Hypoglycemia was the most commonly observed adverse reaction in patients treated with insulin glargine

Supplementary information Acknowledgements We thank the trial participants, investigators and study coordinators for their participation in this study

The procedure should be abandoned if gastric contents are evident

For people who do not meet the eligibility criteria for bariatric surgery and who fail to maintain weight loss through lifestyle interventions, pharmacotherapy is the only remaining option